ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CRBP vs RLYB // PIOTROSKI F-SCORE QUALITY

Corbus Pharmaceuticals Holdings Inc. (NASDAQ) VS. Rallybio Corporation (NASDAQ) • 15-METRIC TALLY: CRBP 0 — RLYB 3
▲ PIOTROSKI F-SCORE QUALITY LEADER: RLYB
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CRBP VS. RLYB) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CRBP RLYB SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — 34.90% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 4.13 — TIE /balance-sheet <GO>
Piotroski F-Score Quality ACTIVE 2/9 3/9 -1.00 RLYB /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 25.6 40.4 -14.84 RLYB /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $81.6M $83.0M -$1.3M RLYB /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CRBP REV RLYB REV CRBP GROSS % RLYB GROSS % CRBP FCF RLYB FCF
FY 2025 $0 $858.0K — — -$64.5M -$29.8M
FY 2024 $0 $636.0K — — -$41.8M -$49.3M
FY 2023 $0 $0 — — -$36.1M -$60.3M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CRBP // BETA —
RLYB // BETA —